DigmBio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Investors
  • 10

DigmBio General Information

Description

Developer of a novel dementia treatment designed to target the T1R3 GPCR. The company offers small-molecule drug discovery, therapeutic research, preclinical development, target identification, and clinical development capabilities to develop therapies for cancer and neurological disorders, enabling pharmaceutical companies, research organizations, and healthcare providers to advance treatments for complex diseases and support the development of new medicines.

Contact Information

Website
www.digmbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Number 901, 9-22, Pangyo-ro, 255 beon-gil, Bundang-gu
  • Seongnam, Gyeonggi 13486
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Number 901, 9-22, Pangyo-ro, 255 beon-gil, Bundang-gu
  • Seongnam, Gyeonggi 13486
  • South Korea

DigmBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DigmBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 29-Jul-2026 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series A) 25-Mar-2025 Completed Clinical Trials - Phase 1
4. Seed Round 01-Oct-2021 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 01-Mar-2021 Completed Startup
2. Angel (individual) 01-May-2020 $245K $245K Completed Startup
1. Accelerator/Incubator Completed Startup
To view DigmBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

DigmBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DigmBio Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cornerstone Investment Partners Asset Manager Minority
Industrial Bank of Korea PE/Buyout Minority
Meritz Securities Investment Bank Minority
Myriad Life Sciences Accelerator/Incubator Minority
Partners Investment Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

DigmBio FAQs

  • When was DigmBio founded?

    DigmBio was founded in 2020.

  • Where is DigmBio headquartered?

    DigmBio is headquartered in Seongnam, South Korea.

  • What is the size of DigmBio?

    DigmBio has 10 total employees.

  • What industry is DigmBio in?

    DigmBio’s primary industry is Drug Discovery.

  • Is DigmBio a private or public company?

    DigmBio is a Private company.

  • What is DigmBio’s current revenue?

    The current revenue for DigmBio is .

  • How much funding has DigmBio raised over time?

    DigmBio has raised $10.6M.

  • Who are DigmBio’s investors?

    Cornerstone Investment Partners, Industrial Bank of Korea, Meritz Securities, Myriad Life Sciences, and Partners Investment are 5 of 10 investors who have invested in DigmBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process